Anthony with Yahoo Finance


anonymous

Guest
This guy is no doubt Mr. Sunshine who posts ridiculously optimistic crap about Esperion. He's all over the Yahoo Finance Board for Esperion posting complete dribble. He's been wrong in everything He's posted over the last two years. No doubt being paid by Esperion to post this or more likely it's some clown in Ann Arbor masquerading as pharma Finance expert. There's no end to what this company will do.
 


This guy is no doubt Mr. Sunshine who posts ridiculously optimistic crap about Esperion. He's all over the Yahoo Finance Board for Esperion posting complete dribble. He's been wrong in everything He's posted over the last two years. No doubt being paid by Esperion to post this or more likely it's some clown in Ann Arbor masquerading as pharma Finance expert. There's no end to what this company will do.
Loser Karen is still stalking Esperion. Cackling and pathetic.
 




Anthony is pretty sharp in his analysis, especially in the high tech biosciences area. Seeing prices targets move up is always a good sign, and being way below these targets can be like dumping jet fuel on a bonfire. The upside is always theoretically unlimited, it’s an exciting time for the space as we transition to an AI focused R&D platform.
 




Anthony is pretty sharp in his analysis, especially in the high tech biosciences area. Seeing prices targets move up is always a good sign, and being way below these targets can be like dumping jet fuel on a bonfire. The upside is always theoretically unlimited, it’s an exciting time for the space as we transition to an AI focused R&D platform.

He's an Ann Arbor employee. Not fooling anyone. The only bonfire at Esperion is investor money. Think about the burn from $78.00 a share to $1.40 in 3 years. Yep Anthony is right on the money.
 










Any of these finance articles you read in any stock forum are all bought and paid for by Esperion. It's such a dead giveaway with the same rosy statements that are made here.
 






Anthony is pretty sharp in his analysis, especially in the high tech biosciences area. Seeing prices targets move up is always a good sign, and being way below these targets can be like dumping jet fuel on a bonfire. The upside is always theoretically unlimited, it’s an exciting time for the space as we transition to an AI focused R&D platform.

Anthony sounds like he was a Scientific Hire in the Finance Business.
Much pablum, like ESPR Scientific Hires, Highly Tenured Customer Facing Team.
 















Write your reply...